Page 210 - Mployee Wellness Programs News Today

The ability to adapt has proven paramount over the past few years and it is fundamentally reshaping healthcare IT. In 2023, that shape will increasingly form around the cloud.

Engineers see everything as a system, know how to design under constraints, and recognize the need for trade-offs. Adopting an engineering mindset in oncology research can fix all the broken constituent processes like patient enrollment to systematize clinical trials.

Hospitals’ operational margins have shrunk dramatically this year. Now more than ever, hospitals need to ensure they’re getting the most out of their investments in technology. Clear governance structures, effective communication and detailed training are among the factors hospitals need in order to get a significant return on investment for technology deployments, according to a new report.

As we look out over the horizon to 2023, we would anticipate a rebound of investment in the digital health space but with a simultaneous and a continuing level of focused regulatory diligence as this complex landscape continues to evolve.

Never has there been a time in healthcare when listening and understanding have been more critical. Issues of today are divisive, complex, and layered without easy solutions. We cannot possibly begin to fix without slowing down to listen through every channel available.

AI chatbots and automated responses are great tools for service providers to leverage when it comes to improving efficiency in customer service. However, while working in health tech with a focus on nutrition support, I have found that many providers lack an element of human connection that you can’t attain as easily from a chatbot. If you want to speak with a real expert 1:1 to help better understand how to take back control of your wellness and improve your health, human connection is one o...

The first regulatory approval of an allogeneic cell therapy goes to Atara Biotherapeutics. Other regulatory news highlights from the past week include proposed reforms of the FDA’s accelerated approval process, approval of the first gene therapy for bladder cancer, and a clinical hold for a biotech developing a new class of medicines.

Blue Cross and Blue Shield of Minnesota formed a value-based arrangement with Minnesota Oncology in 2019. Preliminary data show that it led to a reduction in the total cost of care, emergency visits and inpatient admissions.

The future towards the safer treatment of pain will come as biopharma, and investor communities appreciate the significant opportunities in supporting scientifically rigorous and clinically validated lead assets for the safer treatment of pain.

I write this because of my own personal experience with stealing prescription drugs while employed as a nurse, which led to me serving a four-month jail sentence and losing the career of my dreams.